Onena Medicines develops targeted antibody treatments utilizing advanced AI technology to address cancer, anemia, and obesity. The company focuses on creating precise therapeutic solutions for patients suffering from these conditions, enhancing treatment efficacy and patient outcomes.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer, anemia, and obesity remain significant global health challenges, often requiring treatments with broad systemic effects and limited precision. This can lead to suboptimal efficacy and increased side effects, impacting patient outcomes and quality of life.
Solution
Onena Medicines is developing a portfolio of targeted antibody therapies designed to address cancer, anemia, and obesity with greater precision. By leveraging advanced AI technology, Onena aims to identify and develop antibodies that selectively target disease-specific pathways, minimizing off-target effects and maximizing therapeutic impact. This approach seeks to improve treatment efficacy, reduce adverse events, and ultimately enhance patient outcomes in these challenging disease areas. The company is focused on creating innovative therapeutic solutions that offer a more targeted and effective approach to treating these conditions.
Target Audience
The primary target audience includes patients suffering from cancer, anemia, and obesity, as well as healthcare providers seeking more effective and targeted treatment options.
Features
- AI-driven antibody discovery platform for identifying novel therapeutic targets.
- Development of targeted antibody treatments for cancer, anemia, and obesity.
- Focus on enhancing treatment efficacy and patient outcomes through precision medicine.